ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Sequential Optimization of Multivariate Metal-Organic Framework Based Biocatalysis.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomacromolecule-MOF Composites for Intracellular Delivery: From Empirical Construction to Rational Design and AI-Assisted Screening.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Efficient biocascades require integrated optimization of both biocatalysts and reaction conditions. In the present study, we employ a Latin hypercube sampling-coupled Bayesian optimization (LHS-BO) workflow to sequentially optimizes multivariate Zr-based E-MOF (E-MOF = enzyme@metal-organic framework biocomposite) design and the downstream glucose oxidase-horseradish peroxidase (GOx-HRP) biocascade. Enzymatic assays, attenuated total reflectance Fourier transform infrared spectroscopic (ATR-FTIR) and ultraviolet-visible (UV-Vis) spectroscopic analyses confirm that the optimized multivariate E-MOFs, ZG67, and ZH16, stabilize GOx and HRP in bioactive conformations. ZG67 and ZH16 achieve high encapsulation efficiency (92.2% ± 0.7% and 90.2% ± 1.3%), retained activity (87.1% ± 2.2% and 102.9% ± 14.9%), and enhanced stability under thermal (51.3% ± 1.4% and 45.9% ± 8.7%) and solvent treatments (>80% and ≈60% residual activity, respectively, in ethanol or acetonitrile). The optimal GOx-HRP cascade condition identified by LHS-BO (R49) achieves over 95% of the theoretical maximum 2,3-diaminophenazine (DAP) production rate predicted by the microkinetic model. The strong agreement amongst the experimental data, machine learning modeling, and kinetic modeling validates the robustness of this sequential E-MOF optimization framework. This generalized LHS-BO strategy provides a powerful tool for rational E-MOF and multi-enzyme cascade design, advancing biocatalysis and reaction engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.